CT-CIDRA-MINERALS
19.12.2022 10:01:39 CET | Business Wire | Press release
CiDRA Minerals Processing Inc. (“CiDRA”) and OZ Minerals Ltd (“OZ Minerals”) are pleased to announce that they have entered into a Memorandum of Understanding that provides a basis of common understanding to commission a Front End Engineering Design (FEED) study for customization and tie-in of CiDRA’s proprietary mineral separation technology for operation in a grind circuit rougher application at OZ Minerals’ Carrapateena Mine Site. At the same time, CiDRA and OZ Minerals have agreed to deploy a demonstration plant based on CiDRA’s technology at the site. CiDRA and OZ Minerals share a desire to increase the technology readiness level (TRL) for a commercial scale implementation of CiDRA’s technology as a grind circuit rougher which will process a coarse fraction of the primary grind hydrocyclone underflow at Carrapateena. The goals of the Partnership are to increase plant throughput, recovery, and net metal production at a reduced specific energy consumption in keeping with their efforts to help meet the world’s raw material needs in a responsible, equitable, and sustainable way.
“We are excited to take this next step in our relationship with OZ Minerals. Since early 2022, we have been working closely with the Carrapateena Mine Site to evaluate the potential benefits of CiDRA’s technology. This new technology enables a robust process that can recover mineral particles across a size range from ultra-fine to very coarse with high selectivity and minimal hydraulic entrainment. Applying CiDRA’s novel technology as a grind circuit rougher unlocks the concentrator’s throughput capacity while maintaining world class mineral recovery. The MOU will allow us to collectively focus our efforts to leverage this incredible innovation to enhance the net metal production of the Carrapateena Mine Site and create a tremendous value for each of our companies,” stated Paul Rothman, President of CiDRA.
Joe Seppelt, Manager-Processing at OZ Minerals’ Carrapateena Mine Site stated: “The CiDRA technology can enable us to increase our plant throughput without sacrificing the industry leading recoveries that we have been able to achieve at Carrapateena. This capital efficient approach has the potential to operate with less water and energy and with a smaller footprint. We look forward to working with CiDRA to realize the benefits of their innovation.”
About CiDRA Minerals Processing
CiDRA Minerals Processing develops advanced technologies and solutions that create new paradigms in the minerals processing industry with a focus on increasing enterprise value through optimization, increased recoveries and enhancing the sustainability of limited and valuable resources. CiDRA Minerals Processing provides measurement and control solutions to over 460 mine sites in 46 countries.
About OZ Minerals
At OZ Minerals we strive to be modern. We’re guided by our purpose, “Going beyond what’s possible to make lives better”. We believe that only when we create value for all our stakeholders will we be successful and sustainable. Our framework of systems and behaviours we call The OZWay, guides us while giving us the freedom and pathways to achieve our aspirations and purpose. We are passionate about creating an inclusive culture where people challenge, innovate, learn and grow together. By ethically and responsibly exploring for and mining copper we contribute to a low carbon future and economic wellbeing which, in turn, helps us achieve our purpose and contribute to a better future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
